Results 1 - 9 of 9
Low-priced stocks can be cheap for a good reason, but they might also present some great, overlooked investment opportunities.
A Little Bit of Cash for ArQule
ArQule receives a milestone payment from a partner.
Speculative? Sure. But they all have intriguing compounds in development.
Exelixis' partner requests an early review of its No. 2 drug.
This Chinese biotech outsourcing firm recently went public and has lots of room to grow.
A Fool peers in through Wall Street's out door.
Dendreon Tries to Pick Up the Pieces
Dendreon lays out its preliminary plans following a negative FDA regulatory decision.
Diagnosing Dendreon Postmortem
The FDA issues an approvable letter for Dendreon's top compound.
We're watching for the ultimate growth companies -- are you?
Results 1 - 9 of 9
Legal Information © 1995 - 2008 The Motley Fool. All rights reserved.
Market Data provided by 
Terms & Conditions
RSS Headlines
Fool UK